排名前五的靶点	数量

Nrf2(核转录因子的激活红细胞2相关因子)	5
TfR1(转铁蛋白受体1)	4
SOD1(超氧化物歧化酶)	3
SMN2(运动神经元存活蛋白)	3
α4β1(整合素α-4/β-1复合体)	2

关联

项与 Biogen, Inc. 相关的药物

Motixafortide

莫替沙福肽

靶点

CXCR4

作用机制

CXCR4拮抗剂

在研机构

Ayrmid Pharma Limited [+5]

原研机构

Biokine Therapeutics Ltd.

在研适应症

多发性骨髓瘤 [+8]

非在研适应症

急性淋巴细胞白血病 [+9]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2023-09-08

Zuranolone

祖拉诺龙

靶点

GABAA receptor

作用机制

GABAA receptor 正变构调节剂

在研机构

Biogen, Inc. [+2]

原研机构

SAGE Therapeutics, Inc.

在研适应症

产后抑郁症 [+1]

非在研适应症

躁郁症1型 [+7]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2023-08-04

Tofersen

托夫生

靶点

SOD1

作用机制

SOD1基因抑制剂

在研机构

Biogen Netherlands BV [+6]

原研机构

Ionis Pharmaceuticals, Inc.

在研适应症

肌萎缩侧索硬化 [+1]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2023-04-25

712

项与 Biogen, Inc. 相关的临床试验

NCT06628687

/ RecruitingN/A

A Post-marketing, Observational, Descriptive Study to Assess the Risk Associated With Pregnancy, the Maternal Complications, and Adverse Effects on the Developing Fetus, Neonate, and Infant Among Individuals Exposed to Omaveloxolone During Pregnancy and/or Lactation

In this study, researchers will learn more about the safety of BIIB141, also known as omaveloxolone or SKYCLARYS. This is a drug available for doctors to prescribe for people with Friedrich's Ataxia, also known as FA. This is known as an "observational" study, which collects health information about study participants without changing their medical care. Participants for this study will have taken BIIB141 at any time during pregnancy and/or while breastfeeding or pumping up through the first year after delivery. Participants can join this study on their own or they may be enrolled by their regular doctors. This study is also known as the "SKYCLARYS (Omaveloxolone) Pregnancy and Lactation Surveillance Program."
The main objective of this study is to learn more about how BIIB141 may affect pregnancy, as well as any effects on the health of the mother and of the baby during its first year of life.
The main question researchers want to answer in this study is:
· Does taking BIIB141 during pregnancy or breastfeeding lead to any major birth defects?
Researchers will also learn more about:
* Does taking BIIB141 during pregnancy or breastfeeding lead to any minor birth defects?
* Does taking BIIB141 during pregnancy or breastfeeding affect the following:
* Gestational diabetes, a disease that can happen during pregnancy that affects how your body uses sugar
* Pre-eclampsia, a pregnancy-related high blood pressure disease
* Unborn baby being small for its expected age (usually in weeks)
* Loss of an unborn baby
* Live birth
* Premature birth
* Loss of a newborn
* Growth or developmental delays in the baby
* Serious illness in the baby resulting in hospitalization
* Serious infections in the baby, or ones in babies with a weakened immune system
This study will be done as follows:
* Participants will join the study after signing an informed consent form, also known as an ICF.
* During the study, health information from the participants' regular visits to their doctor will be collected based on whether participant joined the study while pregnant or after the baby is born.
* Each participant will be in the study for up to 1 year after the birth of their child, unless they decide to leave early. Overall, this study is expected to last at least 10 years.

开始日期2026-10-26

申办/合作机构

Biogen, Inc.

NCT07133828

/ Not yet recruiting临床1期

A Phase 1, Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB142 in Healthy Adults

In this study, researchers will learn more about the safety of BIIB142 and how it is processed in the body. This is the first time that researchers will learn about BIIB142 and how it affects people.
The main question researchers want to answer in this study is:
• How many participants have adverse events (AEs) and serious adverse events (SAEs)?
An AE is a health problem that may or may not be caused by a drug during the study. An AE is considered serious when it results in death, is life-threatening, causes lasting problems, or requires hospital care.
Researchers will also learn more about:
• How the body processes BIIB142
This is a "dose escalation study." This is a study in which increasing amounts of the study drug are given to different groups of participants. This is done until researchers find the highest dose that does not cause harmful effects.
First, participants will be screened to check if they can join the study. The screening period will be up to 28 days. This study will be split into 2 parts - Part A and Part B.
During Part A:
* Participants will be randomly placed into 1 of 6 groups to receive a single dose of either BIIB142 or a placebo. A placebo looks like the study drug but contains no real medicine.
* Participants in Groups 1 through 5 will take either BIIB142 or the placebo without food. Participants in Group 6 will take 2 doses of their assigned treatment - once with food and once without food.
* Neither the researchers nor the participants will know if the participants will receive BIIB142 or the placebo.
* Participants will stay at their study research center for 5 days. They will return for another 4 visits. Each participant in Part A will be in the study for up to 58 days.
During Part B:
* Participants will be randomly placed into 1 of 3 groups to receive BIIB142 or the placebo. In Part B, participants will take BIIB142 or the placebo once a day for 14 days.
* Neither the researchers nor the participants will know if the participants will receive BIIB142 or the placebo.
* Participants will stay at their study research center for 16 days. They will return for another 4 visits. Each participant in Part B will be in the study for up to 58 days.

开始日期2025-08-29

申办/合作机构

Biogen, Inc.

NCT07047820

/ RecruitingN/A

Prospective, Observational Survey Study Assessing Effectiveness of Zuranolone in Improving PPD Symptoms in the Real-world Setting

In this study, researchers will learn more about how zuranolone affects the symptoms of postpartum depression, also known as PPD. Zuranolone is a drug that healthcare professionals can prescribe for adults with PPD. After giving birth, adults with PPD can suffer from symptoms such as tiredness, sadness, and a loss of interest in their daily activities.
This study is known as an observational study, which means it collects health information about study participants after a healthcare professional has already prescribed treatment. Participants for this study will be found in the United States using a database from CVS Specialty Pharmacy. This will include anyone who was prescribed zuranolone between June 2025 and May 2026 and who filled the prescription within 1 year after the end of their pregnancy.
The main goal of this study is to learn more about how zuranolone affects the participants' PPD symptoms. This will be measured using a questionnaire completed by participants called the Edinburgh Postnatal Depression Scale, also known as the EPDS. A higher score on the EPDS may indicate more severe PPD symptoms.
The main question researchers want to answer in this study is:
- Do PPD symptoms change after treatment with zuranolone based on EPDS scores measured at Day 15?
Researchers will also learn more about:
* Changes in participants' EPDS scores from before treatment to Day 45, which is 30 days after treatment ends.
* How many participants breastfeed their babies while taking zuranolone
* How many participants do not start new medicine after finishing their zuranolone treatment
* How many participants take new medicines after finishing zuranolone
* How many participants already tried other medicines for their depression symptoms before joining this study
* How many participants take other medicines in general while taking zuranolone
This study will be done as follows:
People who fill their zuranolone prescription through CVS Specialty Pharmacy will be contacted by email or phone to ask them about their interest in participating in the study.
Those who agree to take part will answer written questions about their symptoms using the EPDS tool. They will also answer other survey questions about their background, environment, and general health information. Participants must take their first dose of zuranolone within 7 days of joining the study.
Participants will then be asked to answer questions using the EPDS tools, 15 days and 45 days after taking the first dose of zuranolone.

开始日期2025-06-30

申办/合作机构

Biogen, Inc.

100 项与 Biogen, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Biogen, Inc. 相关的专利（医药）

登录后查看更多信息

2,218

项与 Biogen, Inc. 相关的文献（医药）

2025-08-01·JOURNAL OF ALZHEIMERS DISEASE

Harnessing greater statistical power: Comprehensive evaluation of disease modifying treatment effects across all or multiple post-baseline visits compared to the last visit for Alzheimer's disease clinical trials

Article

作者: Wu, Shuang ; Wang, Whedy ; Bateman, Randall J ; Mangal, Brian ; Inman, Dave ; Guizzetti, Leonard ; Li, Yan ; McDade, Eric ; Wang, Guoqiao ; O’Gorman, John ; Li, CaiYan ; Chen, Tianle

Background:

In Alzheimer's disease (AD) clinical trials, efficacy inference is traditionally based on the last visit (e.g., 18 months). However, recent studies suggest that disease-modifying treatment effects may emerge as early as 3 months post-baseline.

Objective:

To explore this further, our study aimed to assess the increased statistical power achieved by incorporating all or multiple post-baseline visits to estimate treatment effect, compared to relying solely on the last visit.

Methods:

We developed explicit formulas for the basis functions of the natural cubic spline model, ensuring compatibility with standard SAS procedures. Through simulations using disease progression trajectories from Clarity-AD and TRAILBLAZER-ALZ 2 trials, we comprehensively evaluated various models in terms of power and type I error. Additionally, we offer SAS codes that to facilitate seamless implementation of different modeling approaches.

Results:

Simulations based on ClarityAD and TRAILBLAZER-ALZ 2 disease trajectories demonstrated that models incorporating multiple or all post-baseline visits yield greater power than those using only the last visit, while maintaining Type I error control. Furthermore, when three post-baseline visits were included, adding more visits resulted in minimal power gains.

Conclusions:

Our findings support prioritizing statistical models that incorporate multiple or all post-baseline visits for treatment efficacy inference, as they offer greater efficiency than models relying solely on the last visit.

2025-08-01·Journal of Cerebral Blood Flow and Metabolism

In vivo quantification of [ ¹¹ C]BIO-1819578 in non-human primates, a novel radioligand for O-GlcNAcase

Article

作者: Varrone, Andrea ; Arakawa, Ryosuke ; Nag, Sangram ; Halldin, Christer ; Bolin, Martin ; Farde, Lars ; Martarello, Laurent ; Morén, Anton Forsberg ; Kaliszczak, Maciej A

Neurofibrillary tangles (NFTs), composed of aggregated tau protein, in the brain is a neuropathological hallmark and feature of Alzheimer’s disease (AD) and other tauopathies. One promising approach to prevent tau aggregates is to inhibit O-GlcNAcase (OGA), an enzyme that regulates tau O-GlcNAcylation. [ 11 C]BIO-1819578 has emerged as a promising candidate to determine target occupancy of such OGA inhibitor drugs. The aim of this study was to further evaluate the pharmacokinetic properties of [ 11 C]BIO-1819578 in non-human primates (NHPs) and to estimate its effective dose. Kinetic compartment analyses of [ 11 C]BIO-1819578 binding to OGA in the brain were performed on positron emission tomography (PET) measurements conducted in three cynomolgus NHPs. Whole-body PET measurements were carried out in two NHPs to estimate the effective radiation dose. Both the 1-tissue-compartment (1TCM) and 2-tissue-compartment model (2TCM) could describe the regional time activity curves of [ 11 C]BIO-1819578. The 2TCM was the statistically preferred model. The effective radiation dose was estimated to be 0.0033 mSv/MBq. The results showed that [ 11 C]BIO-1819578 has suitable characteristics for reliable quantification of OGA using full kinetic modelling. The effective dose was on par with other 11 C radioligands and is unlikely to pose an issue for human use.

2025-08-01·JPAD-Journal of Prevention of Alzheimers Disease

Lower baseline amyloid beta burden is associated with greater percent of amyloid beta positron emission tomography reduction and better clinical outcomes in the aducanumab Phase 3 trials ENGAGE and EMERGE in early Alzheimer's disease

Article

作者: Brothers, Holly M ; Murphy, Jennifer ; Sun, Tao ; Curiale, Gioacchino ; Dent, Gersham ; Hutchison, R Matthew ; Kowalski, Ken ; Burton, Jackson

BACKGROUND:

Aducanumab is a human immunoglobulin G1 anti-amyloid beta antibody for early-stage Alzheimer's disease. After the discontinuation of the aducanumab clinical program and market withdrawal, the Phase 3 data were further assessed to characterize the relationship between baseline amyloid beta load, degree of amyloid beta removal, and subsequent clinical outcomes to provide context for future research.

OBJECTIVES:

This analysis leveraged modelling techniques to impute missing amyloid beta positron emission tomography values and better understand the relationship between baseline amyloid beta positron emission tomography status, amyloid beta positron emission tomography reduction, and clinical outcomes in the aducanumab Phase 3 ENGAGE and EMERGE (NCT02477800/NCT02484547) studies.

DESIGN:

Exploratory data analysis.

SETTING:

A previously developed model which characterized the relationship between aducanumab exposure and amyloid beta positron emission tomography standard uptake value ratio was updated to impute centiloid values for participants not enrolled in the amyloid beta positron emission tomography substudy. Additional clinically-relevant variables were also summarized.

PARTICIPANTS:

1876 participants with baseline amyloid beta positron emission tomography and clinical endpoints in a pooled ENGAGE/EMERGE dataset at week 78.

INTERVENTION:

Aducanumab MEASUREMENTS: Amyloid burden measured by centiloids and clinical endpoints.

RESULTS:

In older participants whose baseline amyloid beta burden is lower than the average trial population, exposure to aducanumab provides greater clinical benefit across cognitive and functional endpoints.

CONCLUSIONS:

The relationship between baseline amyloid beta load and treatment benefit in a large population after exposure to an amyloid beta-directed antibody provides insight into which subpopulations are likely to benefit from this class of treatment.

6,162

项与 Biogen, Inc. 相关的新闻（医药）

2025-08-28

·Firstwordpharma

Safety concerns may overshadow Prothena's search for a partner on its AD assets

Coming off a series of setbacks in amyloidosis and a recent round of layoffs, Prothena is hoping that early data for its Alzheimer's disease (AD) candidate — as well as the potential of a preclinical asset — will attract a partner. The drugmaker shared results on Thursday from the Phase I ASCENT clinical programme, which is evaluating varying dose levels of a once-monthly, subcutaneous anti–beta-amyloid monoclonal antibody (mAb), PRX012, in patients with early symptomatic AD.While Prothena said the candidate was similarly capable of clearing amyloid plaques compared with the two marketed mAbs, Eli Lilly's Kisunla (donanemab-azbt) and Eisai and Biogen's Leqembi (lecanemab), it was linked to higher overall rates of amyloid-related imaging abnormalities with oedema or effusion (ARIA-E).As a result, the company described PRX012 as having a "non-competitive ARIA-E profile" in patients with early symptomatic AD. Still, Chief Development Officer Chad Swanson reiterated Prothena's goal to secure a partnership to advance development of PRX012, as well as its preclinical beta-amyloid transferrin receptor (TfR) antibody PRX012-TfR.The biotech said that observations from ASCENT, as well as feasibility studies of PRX012-TfR, suggest the antibody "may represent an opportunity to significantly lower the risk of ARIA and quickly reduce amyloid plaque with a once-monthly subcutaneous administration," with findings in mice models demonstrating "increased brain exposure and…rapid targeting of beta-amyloid plaques."Plaque attackThursday's readout included data from 228 participants in the ASCENT-2 portion of the programme with early symptomatic AD who were either heterozygous for APOE4, or non-carriers. Individuals who are homozygous for the gene are at higher risk to experience ARIA when receiving an anti–beta-amyloid mAb.Participants were randomised to receive either a 45-mg, 70-mg, 200-mg or 400-mg dose of PRX012, or placebo. In the 400-mg dose cohort, PRX012 reduced amyloid PET levels to a mean of 27.47 centiloids (CL) at month 12; Kisunla has a defined amyloid negativity threshold of ≤24.1 CL, and Leqembi's is ≤30 CL. However, 41.7% of patients in the high-dose group experienced ARIA-E. Lilly recently presented data from a modified titration schedule of Kisunla showing a 14% incidence rate for the complication (see – Physician Views Results: Kisunla widens its lead over Leqembi with new, safer dosing).Prothena said it does not plan on sharing additional data from ASCENT while it hunts for a partner on its AD assets.

临床结果临床1期基因疗法siRNA

2025-08-27

·GBIHealth

长效HIV预防！吉利德Yeytuo在欧盟获批

药械追踪 No.1 / 半年注射一次！吉利德来那帕韦在欧盟获批用于HIV预防 2025年8月26日，吉利德科学（Nasdaq：GILD）宣布，欧盟委员会 (EC) 已授予其每半年注射一次的HIV-1衣壳抑制剂Yeytuo（来那帕韦）上市许可。该药物被批准用作暴露前预防 (PrEP)，以降低体重不低于35公斤、有较高HIV-1感染风险的成人及青少年因性行为感染HIV-1的风险。来那帕韦是首个也是唯一一个在欧盟27个成员国以及挪威、冰岛和列支敦士登获批的每半年注射一次的PrEP方案。来那帕韦是吉利德首创的长效HIV衣壳抑制剂，是目前全球范围内唯一一款每年仅需使用两次的艾滋病治疗药物（片剂也仅需每周口服一次）。此前，该药已在美国、欧盟、日本等多个国家获批上市，用于治疗多重耐药HIV感染，商品名萨兰卡（Sunlenca），用于预防HIV适应证的商品名为Yeytuo。 ->点击文末阅读原文，解锁完整双语新闻 No.2 / 卫材/渤健仑卡奈单抗于欧洲商业上市，首批落地奥地利和德国近日，卫材和渤健宣布，其人源化抗可溶性聚集淀粉样蛋白-β（Aβ）单克隆抗体仑卡奈单抗（商品名：乐意保）已于2025年8月25日在奥地利正式上市，并将于2025年9月1日在德国正式上市。仑卡奈单抗于2025年4月获得欧盟委员会（EC）的批准，成为首个针对阿尔茨海默病（AD）潜在病因的治疗药物。仑卡奈单抗适用于治疗经临床诊断为轻度认知障碍及轻度痴呆的早期阿尔茨海默病（AD）成人患者，且为载脂蛋白E ε4（ApoE ε4）非携带者或杂合子，并经确认存在β-淀粉样蛋白病理。德国和奥地利将成为欧盟首批商业上市该药物的国家。目前，奥地利和德国已正式建立可控准入计划计划（Controlled Access Program），推动该药物在这两个欧盟首批国家顺利上市。仑卡奈单抗的全球开发和注册申请由卫材主导，而产品则由卫材和渤健共同商业化和推广。其中，卫材拥有最终决策权。在欧盟（北欧国家除外），卫材与渤健将共同推广该药物，由卫材作为上市许可持有人负责产品的分销。 ->点击文末阅读原文，解锁完整双语新闻企业动态 No.1 / 复星医药授予Sitala小分子抑制剂FXS6837中国以外权益，获500万美元股权及6.7亿美元付款 2025年8月27日，上海复星医药（集团）股份有限公司（复星医药，600196.SH/2196.HK）宣布，其控股子公司复星医药产业与英国生物技术公司Sitala达成《许可协议》。复星医药产业授予Sitala在除中国（包括港澳台地区）外的全球范围，针对人类、动物疾病的诊断和治疗领域，开发、生产及商业化FXS6837及含有该活性成分产品的权利。FXS6837是复星医药集团拥有自主知识产权的小分子抑制剂，拟用于免疫调节领域相关疾病的治疗。目前，FXS6837的相关适应证于中国境内处于II期临床试验阶段。根据约定，Sitala 将就本次合作向复星医药产业支付至多1.9亿美元不可退还的首付款（2500万美元）、开发及商业化里程碑付款，以及基于许可产品于许可区域的年度净销售额支付至多4.8亿美元的销售里程碑款项。同时，复星医药产业（或其指定关联方）可以零对价获得价值500万美元的Sitala的股份，预计对Sitala的持股比例不超过10%（全面摊薄后）。此外，Sitala还应根据许可产品于许可区域内的年度净销售额，按约定的至多两位数百分比向复星医药产业支付特许权使用费。 ->点击文末阅读原文，解锁完整双语新闻全球医疗情报领导者解锁隐藏在数据中的商业潜力关于 G B I ” 自从2002年成立以来，GBI始终以技术为驱动，为药企、器械及行业相关服务商提供贯穿生命周期的全球药品市场竞争数据、全球行业资讯、HCPs洞察、全国医疗器械数据等商业信息与洞察，助力企业在进行战略布局和决策时，脱颖而出。历经20余年的深耕细作GBI已成为95%以上跨国药企、国内头部药企、咨询与投资机构等医疗圈灯塔用户值得信赖的长期合作伙伴。联系我们投稿 | 发稿 | 媒体合作 ▶ olivia.xu@generalbiologic.com 数据库 | 咨询服务 | 资讯追踪 ▶ 点击左下“阅读原文”完成表单填写点击阅读原文，解锁完整双语新闻

引进/卖出上市批准

2025-08-27

·医药健闻

礼来、强生、罗氏、辉瑞、阿斯利康、武田等全球35家大药厂2025年第二季度和上半年财报业绩汇总

注：各大公司财政年度的起始时间不同于自然年，因此会出现财政季度、年度等与自然年不一致的情况。美国礼来(Eli Lilly and Company)公布2025年第二季度业绩。季度净营收为155.58亿美元，上年同期为113.03亿美元，同比增长38%。季度营业利润68.67亿美元，上年同期为37.15亿美元，同比增长85%。季度净利润56.61亿美元，上年同期为29.67亿美元，同比增长91%。艾伯维(AbbVie)公布2025年第二季度业绩。季度净营收为154.23亿美元，上年同期为144.62亿美元。季度营业利润48.94亿美元，上年同期为39.98亿美元。季度归属公司的净利润9.38亿美元，上年同期为13.7亿美元。强生(Johnson & Johnson)公布2025年第二季度业绩。季度销售额为237.43亿美元，上年同期为224.47亿美元，同比增长5.8%。季度净利润55.37亿美元，上年同期为46.86亿美元，同比增长18.2%。调整后的净利润66.99亿美元，上年同期为68.4亿美元，同比下降2.1%。其中，创新制药业务销售额152.01亿美元，同比增长4.9%。医疗器械业务销售额85.41亿美元，同比增长7.3%。辉瑞(Pfizer)公布2025年第二季度业绩。季度总营收为146.53亿美元，上年同期为132.83亿美元，同比增长10%。季度归属公司普通股东的净利润29.1亿美元，上年同期为4100万美元。默沙东(MSD)公布2025年第二季度业绩。季度销售额为158.06亿美元，上年同期为161.12亿美元，同比下降2%。季度净利润44.27亿美元，上年同期为54.55亿美元，同比下降19%。其中，制药业务销售额140.5亿美元，上年同期为144.08亿美元，同比下降2%。动物保健业务销售额16.46亿美元，，上年同期为14.82亿美元，同比增长11%。百时美施贵宝(Bristol Myers Squibb)公布2025年第二季度业绩。季度总营收为122.69亿美元，上年同期为122.01亿美元。季度归属公司的净利润13.1亿美元，上年同期为16.8亿美元。生物技术公司安进(Amgen)公布2025年第二季度业绩。季度总营收为91.79亿美元，上年同期为83.88亿美元。季度营业利润26.56亿美元，上年同期为19.09亿美元。季度净利润14.32亿美元，上年同期为7.46亿美元。吉利德科学(Gilead Sciences)公布2025年第二季度业绩。季度总营收为70.82亿美元，上年同期为69.54亿美元。季度营业利润24.74亿美元，上年同期为26.44亿美元。季度归属公司的净利润19.6亿美元，上年同期为16.14亿美元。再生元制药(Regeneron)公布2025年第二季度业绩。季度营收为36.76亿美元，上年同期为35.47亿美元。季度营业利润10.8亿美元，上年同期为10.7亿美元。季度净利润13.92亿美元，上年同期为14.32亿美元。晖致(Viatris)公布2025年第二季度业绩。季度总营收为35.82亿美元，上年同期为37.97亿美元。季度营业利润2.33亿美元，上年同期营业亏损2.4亿美元。季度净亏损460万美元，上年同期净利润3.26亿美元。福泰制药(Vertex Pharmaceuticals)公布2025年第二季度业绩。季度总营收为29.65亿美元，上年同期为26.46亿美元。季度营业利润11.51亿美元，上年同期净亏损35.15亿美元。季度净利润10.33亿美元，上年同期净亏损35.94亿美元。渤健(Biogen)公布2025年第二季度业绩。季度总营收为26.46亿美元，上年同期为24.65亿美元。季度归属公司的净利润6.35亿美元，上年同期为5.84亿美元。欧加隆(Organon)公布2025年第二季度业绩。季度营收为15.94亿美元，上年同期为16.07亿美元。季度净利润1.45亿美元，上年同期为1.95亿美元。雅培(Abbott)公布2025年第二季度业绩。季度净销售额111.42亿美元，上年同期为103.77亿美元，同比增加7.4%。季度营业利润20.52亿美元，上年同期为16.69亿美元，同比增长23%。季度净利润17.79亿美元，上年同期为13.02亿美元，同比增长36.7%。其中，营养业务销售额22.12亿美元，诊断业务销售额21.73亿美元，制药业务销售额13.83亿美元，医疗设备业务销售额53.69亿美元。欧洲罗氏(Roche)公布2025年上半年业绩。当期集团销售额309.44亿瑞士法郎，上年同期为298.48亿瑞士法郎。当期营业利润120.1亿瑞士法郎，上年同期为112.93亿瑞士法郎。当期按国际财务准则的净利润78.32亿瑞士法郎，上年同期为66.97亿瑞士法郎。其中，制药业务销售额239.85亿瑞士法郎(约296亿美元)，营业利润125.22亿瑞士法郎。诊断业务销售额69.59亿瑞士法郎，营业利润12.5亿瑞士法郎。阿斯利康(AstraZeneca)公布2025年第二季度业绩。季度总营收144.57亿美元，上年同期为129.38亿美元，同比增长12%。季度营业利润35.08亿美元，上年同期为27.46亿美元，同比增长28%。季度税后利润24.48亿美元，上年同期为19.28亿美元，同比增长27%。诺华(Novartis)公布2025年第二季度业绩。季度净销售额140.54亿美元，上年同期为125.12亿美元，同比增长12%。季度营业利润48.64亿美元，上年同期为40.14亿美元，同比增长21%。季度净利润40.24亿美元，上年同期为32.46亿美元，同比增长24%。诺和诺德(Novo Nordisk)发布2025年上半年业绩。当期净销售额1549.44亿丹麦克朗(约241亿美元)，上年同期为1334.09亿丹麦克朗，同比增长16%。营业利润722.4亿丹麦克朗，上年同期为577.8亿丹麦克朗，同比增长25%。净利润555.37亿丹麦克朗，上年同期为454.57亿丹麦克朗，同比增长22%。其中，第二季度营收768.6亿丹麦克朗(约120亿美元)，净利润为265亿丹麦克朗。赛诺菲(Sanofi)公布2025年第二季度业绩。季度集团净销售额99.94亿欧元(约116亿美元)，上年同期为94.27亿欧元，同比增长6%。季度营业利润14.73亿欧元，上年同期为15.32亿欧元。季度归属股东的净利润39.39亿欧元，上年同期为11.13亿欧元。葛兰素史克(GSK)公布2025年第二季度业绩。季度营业额79.86亿英镑(约107亿美元)，上年同期为78.84亿英镑。季度营业利润20.23亿英镑，上年同期为16.46亿英镑。季度归属股东的净利润14.43亿英镑，上年同期为11.73亿英镑。勃林格殷格翰(Boehringer-Ingelheim)发布2025年上半年业绩报告。当期集团净销售额同比增长6.3%，达140亿欧元。业绩增长主要受益于人用药品业务关键产品的强劲需求。上半年，人用药品业务净销售额同比增长5.7%，达113亿欧元(约131亿美元)。动物保健业务净销售额同比增长7.6%，达26亿欧元。拜耳(Bayer Group)公布2025年第二季度业绩。季度集团销售额107.39亿欧元，上年同期为111.44亿欧元。季度EBIT利润1300万欧元，上年同期为5.25亿欧元。季度净亏损1.99亿欧元，上年同期净亏损2400万欧元。按业务划分，作物科学部门销售额47.88亿欧元，EBIT亏损4.14亿欧元。处方药部门销售额44.7亿欧元(约51.9亿美元)，EBIT利润7.98亿欧元。健康消费品部门销售额14.27亿欧元，EBIT利润2.29亿欧元。德国制药和化工巨头默克集团(Merck Group)公布2025年第二季度业绩。季度净销售额52.55亿欧元，上年同期为53.52亿欧元。季度营业利润(EBIT)8.91亿欧元，上年同期为7.92亿欧元。季度税后利润6.55亿欧元，上年同期为6.05亿欧元。其中，生命科学业务净销售额22.67亿欧元(约26.3亿美元)，上年同期为22.58亿欧元。医药健康业务净销售额21.02亿欧元(约24.4亿美元)，上年同期为21.37亿欧元。电子科技业务净销售额8.86亿欧元，上年同期为9.57亿欧元。仿制药企业山德士(Sandoz)公布2025年上半年业绩。当期净销售额52.32亿美元，上年同期为50.47亿美元，同比增长4%。营业利润6.02亿美元，上年同期为3.32亿美元，同比增长81%。净利润3.77亿美元，上年同期为1.51亿美元。费森尤斯集团(FRESENIUS GROUP)公布的2025年第二季度业绩。季度集团营收55.71亿欧元，上年同期为54.14亿欧元。季度EBIT利润6.54亿欧元，上年同期为6.6亿欧元。季度净利润4.12亿欧元，上年同期为3.88亿欧元。其中￰c费森尤斯卡比(Fresenius Kabi)营收21.11亿欧元(约24.5亿美元)，EBIT利润3.46亿欧元。费森尤斯赫里奥斯诊所(Fresenius Helios)营收33.7亿欧元，EBIT利润3.37亿欧元。基立福(Grifols)公布2025年第二季度和上半年业绩。第二季度净营收18.91亿欧元(约22亿美元)，调整后的EBITDA利润4.75亿欧元，集团净利润1.17亿欧元。上半年净营收36.77亿欧元(约42.74亿美元)，调整后的EBITDA利润8.76亿欧元，集团净利润1.77亿欧元。优时比(UCB)公布2025年上半年业绩。当期营收34.87亿欧元(约40.53亿美元)，上年同期为27.91亿欧元。当期调整后的EBITDA利润10.33亿欧元，上年同期为6.52亿欧元。当期归属股东的净利润4.75亿欧元，上年同期为2.08亿欧元。特药领域生物制药公司益普生(Ipsen)公布2025年上半年财务业绩。当期总销售额18.2亿欧元(约21.15亿美元)，上年同期为16.59亿欧元，同比增长9.7%。核心营业利润6.56亿欧元，上年同期为5.38亿欧元，同比增长21.9%。核心合并净利润5.08亿欧元，上年同期为3.99亿欧元。亚太武田制药(Takeda)公布截至2025年6月30日的第一财季业绩。季度营收11066.85亿日元(约74.65亿美元)，上年同期为12079.9亿日元。营业利润1845.66亿日元，上年同期为1663.29亿日元。归属母公司所有者的净利润1242.43亿日元，上年同期为952.48亿日元。梯瓦制药(Teva Pharmaceutical Industries)公布2025年第二季度业绩。季度净营收为41.76亿美元，上年同期为41.64亿美元。季度营业利润4.55亿美元，上年同期营业亏损500万美元。季度归属公司的净利润2.82亿美元，上年同期为净亏损8.46亿美元。澳大利亚生物制药公司CSL Group公布截至2025年6月30日的财年业绩。全年总营收155.58亿美元，上年为148亿美元，同比增长5%。全年归属公司股东的税后净利润32.19亿美元，上年为29.07亿美元，同比增长14%。安斯泰来(Astellas Pharma)公布截至2025年6月30日的第一财季业绩。季度营收5057.94亿日元(约34.12亿美元)，上年同期为4731.24亿日元。营业利润946.47亿日元，上年同期为506.57亿日元。归属母公司所有者的净利润684.22亿日元，上年同期为376.03亿日元。第一三共(Daiichi Sankyo Company, Limited)公布截至2025年6月30日的第一财季业绩。季度营收4745.97亿日元(约32亿美元)，上年同期为4361.75亿日元，同比增长8.8%。营业利润963.07亿日元，上年同期为728.82亿日元，同比增长32.1%。归属母公司所有者的净利润855亿日元，上年同期为853.83亿日元。大冢控股(Otsuka Holdings)公布2025年上半年业绩。当期营收11807.66亿日元，上年同期为11089.3亿日元，同比增长6.5%。季度营业利润2421.18亿日元，上年同期为1262.79亿日元，同比增长91.7%。季度归属公司所有者的净利润1735.29亿日元，上年同期为1077.95亿日元，同比增长61%。其中，制药业务营收8337.82亿日元(约56.26亿美元)，利润2138.73亿日元。营养业务营收2760.57亿日元，利润360.43亿日元。消费品业务营收158.45亿日元，利润126.54亿日元。卫材(Eisai Co., Ltd.)公布截至2025年6月30日的第一财季业绩。季度营收2026.51亿日元(约13.67亿美元)，上年同期为1890.29亿日元，同比增长7.2%。营业利润207.44亿日元，上年同期为134.07亿日元，同比增长54.7。归属母公司所有者的净利润144.74亿日元，上年同期为105.81亿日元，同比增长36.8%。联系美通社 +86-10-5953 9500 info@prnasia.com

财报疫苗

100 项与 Biogen, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Biogen, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年09月06日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

临床1期

临床2期

临床3期

批准上市

其他

106

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

富马酸二甲酯 ( Nrf2 )	复发-缓解型多发性硬化更多	批准上市
诺西那生钠 ( SMN2 )	脊髓性肌萎缩更多	批准上市
达克珠单抗 ( IL2RA )	复发-缓解型多发性硬化更多	批准上市
达伐吡啶 ( Potassium channel )	多发性硬化症更多	批准上市
干扰素β-1a(Biogen, Inc.) ( IFNAR )	多发性硬化症更多	批准上市